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Abstract
It is generally assumed that recurrent mutations within a given cancer driver gene elicit similar 
drug responses. Cancer genome studies have identified recurrent but divergent missense mutations 
in the substrate recognition domain of the ubiquitin ligase adaptor SPOP in endometrial and 
prostate cancer. Their therapeutic implications remain incompletely understood. Here, we 
analyzed changes in the ubiquitin landscape induced by endometrial cancer-associated SPOP 
mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that 
are preferentially degraded by endometrial SPOP mutants. The resulting reduction of BET protein 
levels sensitized cancer cells to BET inhibitors. Conversely, prostate cancer-specific SPOP mutants 
impaired degradation of BETs, promoting resistance against their pharmacologic inhibition. These 
results uncover an oncogenomics paradox, whereby mutations within the same domain evoke 
opposing drug susceptibilities. Specifically, we provide a molecular rationale for the use of BET 
inhibitors to treat endometrial but not prostate cancer patients with SPOP mutations.
Specific cancer gene mutations can indicate whether a cancer patient may or may not 
respond to a given drug1. Generally, it is assumed that recurrent mutations within a specific 
gene have similar therapeutic implications, especially, if the amino acid changes occur 
within the same protein-encoding domain. Genome studies have revealed recurrent point 
mutations within the substrate recognition domain of the encoding ubiquitin ligase adaptor 
speckle-type POZ protein (SPOP) in 4-14% of prostate and endometrial cancers (Fig. 1a)2–
6. In prostate cancer, SPOP mutations are confined to amino acid residues of the substrate-
binding cleft - a specific region within the substrate-recognition domain that is essential for 
substrate interaction and ubiquitin transfer7. We and others have subsequently shown that 
these mutations act in a dominant-negative fashion to repress ubiquitylation and degradation 
of oncogenic substrate proteins8–12. In contrast, recurrent amino acid substitutions in 
endometrial cancer and carcinosarcoma occur in an uncharacterized territory of the substrate 
recognition domain (Fig. 1a and Supplementary Fig. 1a)4–6. Given the divergent mutation 
pattern in these tumor types, we speculated that endometrial cancer SPOP mutations might 
differently affect protein ubiquitylation, possibly resulting in distinct therapeutic 
opportunities.
Results
Cancer type-specific SPOP mutations have opposing effects on BET protein levels
To explore this hypothesis, we characterized the changes in the ubiquitination landscape 
specific to endometrial cancer SPOP mutations by mass-spectrometry-based proteomics. To 
ensure that disease relevant proteins are being expressed in our experimental setting, we 
chose human Ishikawa endometrial cancer cells, derived from a well-differentiated 
endometrioid cancer, because their robustly expressed genes significantly overlayed with 
those found in SPOP-mutant tumor tissues (Supplementary Fig. 1b)6,13. Subsequently, we 
stably overexpressed control vector (control); SPOP wild-type (SPOP-WT); or seven 
mutated SPOP variants (SPOP-E47K, -E50K, -E78K, -S80R, -M117V, -R121Q, -D140N 
(SPOP-MTs) (Supplementary Fig. 1c) in these cells. In each case, we measured glycine-
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glycine remnants of ubiquitylated lysines (K-ɛ-GG) after trypsin digestion and stable isotope 
labeling of amino acids in cell culture (SILAC)–based mass-spectrometry (LC-MS/MS) 
(Supplementary Fig. 1d)14. All K-ɛ-GG values (n = 17 239) were normalized to protein 
abundance to account for ubiquitylation-related changes in protein expression 
(Supplementary Table 1). K-ɛ-GG-peptide values of individual SPOP-MTs were compared 
to cells overexpressing SPOP-WT within experiments (Supplementary Fig. 2a,c,e,g).
Because protein ubiquitylation is often linked to proteasomal degradation, we asked which 
differentially expressed K-ɛ-GG peptides showed an inverse correlation with protein 
expression (Supplementary Table 1 and Supplementary Fig. 2b,d,f,h). Thereby, we identified 
two patterns of ubiquitination and protein dysregulation in known and putative SPOP 
substrates pointing to possible private contact points between individual substrates and the 
mutant MATH domain (Fig. 1b,c and Supplementary Figs. 2,3a). Peptides corresponding to 
TRIM24, AGR2, and NCOA3 – all proteins with reported oncogenic properties - showed a 
decrease in K-ɛ-GG abundance followed by a raise in corresponding protein levels9,15,16. 
Similar dominant-negative patterns of substrate dysregulation have been reported for 
TRIM24 and NCOA3 by prostate cancer SPOP mutations8,9,17.
The most striking changes were found in proteins that exhibited a robust up-regulation of K-
ɛ-GG peptides coupled with down-regulation of the corresponding protein (Fig. 1b,c and 
Supplementary Fig. 2,3a), including DEK, another characterized SPOP substrate8. Yet, the 
most profound protein changes without concurrent changes at the mRNA level were found 
in BRD3, BRD2, and BRD4 (Fig. 1b,c and Supplementary Fig. 3b). These bromodomain 
and extra-terminal (BET) motif containing proteins, which serve as promising targets for 
cancer therapy18, may be increasingly ubiquitylated and degraded by endometrial cancer 
SPOP mutants. Importantly, similar changes were found also in human HEC-151 and 
RL-952 endometrial cancer cells, and in human 22Rv1 prostate cancer cells (Supplementary 
Fig. 3c-e).
Because prostate cancer SPOP mutants have been found to impair ubiquitylation of 
substrates in a dominant-negative manner, we speculated that these mutants might have an 
opposite effect on BET protein levels8–11. Indeed, over-expression of recurrent prostate 
cancer mutants increased BET protein levels in human Ishikawa endometrial cancer cells, 
human 22Rv1 prostate cancer, human LHMAR prostate epithelial cells8 (Fig. 1d,e and 
Supplementary Fig. 3f-h) and in mouse prostate epithelial cells19. In aggregate, our findings 
suggest that BET proteins might represent SPOP substrates that become differentially 
ubiquitylated and degraded by endometrial and prostate cancer mutants irrespective of 
cellular lineage. In support, nuclear levels of BET proteins correlated inversely with 
recurrent SPOP mutations in human primary endometrial cancer tissues analyzed by 
immunohistochemistry, whereas a positive correlation in human primary prostate cancer 
tissues was noted (Fig. 1f,g and Supplementary Fig. 4).
BET proteins are bona fide SPOP substrates
We sought to determine whether SPOP directly interacts with BET proteins to promote 
ubiquitylation. In agreement, the primary amino acid sequence of BET proteins contained a 
conserved consensus of SPOP-binding motif (Fig. 2a)7. We focused on BRD3 for 
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experimental follow up, because it was the most differentially regulated BET family member 
(Fig. 1b). First, we overexpressed HA-tagged BRD3 harboring three threonine-to-alanine 
substitutions at the binding motif (Degron-MT) (Supplementary Fig. 5a) and assessed the 
ability of SPOP-WT to mediate BRD3 degradation. Indeed, the degron-variant abolished the 
repressive effect of SPOP and produced elevated levels of BRD3 protein, in agreement with 
the notion that also endogenous SPOP was not able to degrade the degron-variant (Fig. 2b 
and Supplementary Fig. 5b). To determine whether this motif mediated direct binding of 
SPOP to BRD3, we performed immunoprecipitation experiments in cells expressing either 
wild-type HA-BRD3 or the degron variant. Whereas SPOP protein was detectable after 
immunoprecipitation of HA-BRD3, the BRD3 degron variant disrupted the BRD3-SPOP 
interaction (Fig. 2c). Thus, the SPOP-binding motif within BRD3 appeared necessary for 
SPOP binding.
Next, we tested whether SPOP could ubiquitylate BRD3 as part of a CUL3-RBX1 ubiquitin 
E3 ligase complex20. Knockdown of CUL3 increased HA-BRD3 levels and decreased 
BRD3 ubiquitylation (Supplementary Fig. 5c). Furthermore, SPOP-WT along with RBX1 
and CUL3 directly ubiquitylated HA-BRD3 in vivo and in vitro, whereas the degron variant 
of HA-BRD3 remained unaffected (Fig. 2d and Supplementary Fig. 5d). Additional CUL3-
dependent substrate adaptors (KLHL9, KLHL13, KLHL21) failed to ubiquitylate BRD3 in 
vitro and thus verified the specificity of SPOP towards BRD3 (Supplementary Fig. 5d).
To determine if BRD3 ubiquitylation induces its proteasomal degradation, we cultured 
SPOP- and BRD3-expressing cells in the presence or absence of the proteasome inhibitor 
MG132. Short-term MG132 treatment increased ubiquitylated HA-BRD3 (Fig. 2d). 
Prolonged proteasomal inhibition, increased HA-BRD3 and endogenous BET protein levels 
in the presence of SPOP-WT overexpression (Fig. 2e and Supplementary Fig. 5e). SPOP 
protein was also detectable after immunoprecipitation of endogenous BET proteins 
(Supplementary Fig. 5f). Moreover, SPOP knockdown increased BET protein levels without 
concomitant mRNA changes and impaired protein degradation after inhibition of protein 
synthesis with cycloheximide (Fig. 2f and Supplementary Fig. 5g, h). In aggregate, these 
data are consistent with a model in which ubiquitylation of BET proteins promote their 
proteasomal degradation.
Cancer type-specific SPOP mutants induce differential ubiquitylation of BET proteins
To test if the functional properties of endometrial cancer SPOP mutants may translate into 
reduced BET protein levels when expressed at the endogenous level, we identified in the 
Cancer Cell Line Encyclopedia the human endometrial cancer cell line EN that harbors a 
recurrent SPOP-R121Q mutation (Supplementary Fig. 6a). We compared BET protein levels 
of EN cells to Ishikawa cells with equal levels of wild type SPOP (Fig. 3a). Indeed, EN 
cancer cells exhibited lower levels of BET proteins, despite higher levels of corresponding 
mRNAs (Fig. 3a and Supplementary Fig. 6b). In line with the notion that enhanced protein 
degradation by SPOP-R121Q reduced BET protein levels in EN cells, we found more 
significant increases of BET protein levels upon SPOP depletion or short-term proteasome 
inhibition in EN cells compared to Ishikawa cells (Fig. 3b and Supplementary Fig. 6c-e). In 
addition and consistent with our observations above, endogenous SPOP-R121Q bound more 
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efficiently to BET proteins in EN cells in which we noted a more pronounced degradation of 
BET proteins after inhibition of protein synthesis with cycloheximide (Fig. 3c and 
Supplementary Fig. 6f,g). Of note, endogenous SPOP levels were also increased after 
prolonged proteasome inhibition and reduced after inhibition of protein synthesis, indicating 
a proteasomal turnover of SPOP itself (Fig. 2e and Fig. 3b,c).
To test if altered BET protein binding and degradation kinetics in human EN and Ishikawa 
cells were a result of specific amino acid substitutions within SPOP, we analyzed the effects 
of different SPOP species side-by-side in the same cellular context. Endometrial cancer 
SPOP-E50K and SPOP-R121Q mutants bound more strongly to HA-BRD3 than SPOP-WT 
in vivo and in vitro, whereas the interaction was reduced with the prostate cancer SPOP-
W131G and SPOP-F133L mutants, respectively (Fig. 3d and Supplementary Fig. 6h). In 
line, ubiquitylation of HA-BRD3 was increased by the endometrial cancer and decreased by 
prostate cancer SPOP mutants, respectively (Fig. 3e and Supplementary Fig. 6i). We next 
investigated if the increase in ubiquitylation mediated by the endometrial cancer SPOP 
mutants is dependent on the intact degron on BRD3. Indeed, SPOP-E50K failed to 
ubiquitylate the degron variant of BRD3 (Fig. 3f) and to reduce its protein levels 
(Supplementary Fig. 6j). These results suggest that BET protein levels are at least in part 
affected by differential interaction between SPOP mutants and the BET degron.
Sensitivity to BET inhibitors is altered by cancer type-specific SPOP mutants
Some cancer cells typically depend on the presence of BET proteins for tumor growth and 
survival18,21. Therefore, we wondered whether enhanced degradation of BET proteins in 
the context of endometrial cancer SPOP mutant might create specific vulnerabilities. We 
speculated that endometrial cancer cells with low BET protein levels might become 
particularly susceptible to further reduction of BET proteins. Indeed, the growth of EN cells 
were susceptible to single knockdown of BET proteins (Supplementary Fig. 7a). To achieve 
a similar effect in Ishikawa cells, individual BET proteins had to be knocked down in the 
context of SPOP-R121Q over-expression, in analogy to EN cells. These data suggest that 
endometrial cancer cells with low BET protein levels in the context of endometrial cancer 
SPOP mutant are particularly susceptible to further suppression of BET protein function. In 
support of this view, a functional overlap among BET proteins has been reported22.
BET inhibitors are under clinical investigation as anti-cancer therapeutics, including solid 
tumors18,21,23,24. We anticipated that the susceptibility of cancer cells to these inhibitors 
might be influenced by BET protein level changes in response to SPOP mutants. Indeed, 
forced expression of endometrial cancer SPOP mutants (shown previously to lower BET 
protein levels) sensitized Ishikawa cells to both BET inhibitors JQ1 and OTX-015 by 
promoting apoptosis and reducing cellular proliferation (Fig. 4a and Supplementary Fig. 7b-
e)25,26. Similar results were also found in HEC151 and RL952 endometrial cancer cells 
(Supplementary Fig. 7f). We wondered whether BET protein level changes contribute to JQ1 
sensitivity. To this end, reduced level of the individual BET proteins in response to SPOP 
mutants in Ishikawa cells correlated with the decrease of the half maximal inhibitory 
concentration (IC50) after JQ1 treatment (Fig. 4b). Functionally, overexpression of BRD2, 
BRD3, and BRD4 degron variants lowered SPOP-E50K-mediated JQ1 sensitization (Fig. 4c 
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and Supplementary Fig. 7g). We then investigated whether increased BET protein levels in 
the context of prostate cancer may on the contrary induce resistance to BET inhibitors. 
Overexpression of prostate cancer SPOP mutants rendered Ishikawa cells and 22Rv1 more 
resistant to JQ1 (Fig. 4a and Supplementary Fig. 7h,i), while individual (Fig. 4d and 
Supplementary Fig. 7j,l) or combined knockdown (Supplementary Fig. 7k) of BET proteins 
in the context of SPOP-Y87C mutant dampened this phenotype.
Next, we wondered if recurrent SPOP mutations or decreased BET protein levels in general 
may predict sensitivity to pharmacological BET inhibition across human endometrial cancer 
cell line models. For this purpose, we assessed JQ1-sensitivity in 3D semi-solid culture 
conditions across 12 different human cell lines for which we determined BET protein levels 
in parallel. Decreased expression levels of BRD2, BRD3, and BRD4 was associated in many 
cases with sensitivity to JQ1 (Supplementary Fig. 8a-c), however we noted also some 
remarkable exceptions to this rule in agreement with the existence of other molecular 
mechanisms that regulate BET inhibitor susceptibility27,28. Nevertheless, SPOP-R121Q-
mutant EN cells were sensitive to JQ1 inhibition in line with our previous data generated in 
isogenic cell lines (Fig. 4a,e and Supplementary Fig. 7f, 8b). This finding let us to search for 
additional cell lines with recurrent endometrial cancer-associated SPOP mutations at the 
endogenous locus. We identified in the Cosmic Cell Line Project a colorectal and a 
urothelial cancer cell line that harbor a SPOP-E47K (NCI-H508) and SPOP-E50K (VM-
CUB1) mutation, respectively. Both cell lines were particularly sensitivity to JQ1 and 
displayed low BET protein levels that were responsive to proteasomal inhibition (Fig. 4e and 
Supplementary Fig. 8d). Thus, endometrial cancer-associated SPOP mutations may possibly 
be more broadly associated with BET inhibitor sensitivity.
Moreover, we tested if established SPOP substrates may influence either directly or 
indirectly JQ1 responses through changes in BET proteins levels. Neither knockdown nor 
overexpression of DEK, TRIM24, NCOA3, nor ERG lead to significant changes of BET 
protein levels or JQ1 responses, further supporting the notion that SPOP mutants affect JQ1 
sensitivity directly through regulation of BET protein degradation (Supplementary Fig. 9).
Transcriptome analysis identifies FOSL1 as determinant of JQ1 response
BET inhibitors bind to the bromodomains of BET proteins to displace them from acetylated 
histone tails of transcriptionally active sites. Given this function, we interrogated the 
transcriptional changes in response to over-expression of wild type SPOP or two recurrent 
endometrial and prostate cancer SPOP mutants in Ishikawa cells (Supplementary Table 2). 
Unsupervised clustering and multidimensional scaling (MDS) analysis revealed mainly 
opposing changes of endometrial and prostate cancer SPOP mutants, whereby wild type 
SPOP positioned in between the different types of SPOP mutants (Supplementary Fig. 10a-
b). This result aligns well with the BET protein level changes across the different cell lines 
observed earlier (Supplementary Fig. 3f). Interestingly, the MDS analysis revealed a second 
feature that discriminated both types of mutants from wild type SPOP, possibly reflecting 
shared dysregulation of SPOP substrates such as TRIM24 or NCOA3 (Fig. 1c and 
Supplementary Fig. 10b)8.
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Next, we interrogated the transcriptional changes under JQ1 treatment in endometrial versus 
prostate cancer SPOP mutants and found a significant overlap with the genes altered in the 
untreated conditions (Fig. 5a,b and Supplementary Fig. 10a-c). We identified 16 genes that 
were shared across all conditions (untreated, 500 nM and 2 μM JQ1 treated) including 
FOSL1 – a reported BET protein target gene implicated in BET inhibitor sensitivity29. 
FOSL1 mRNA and protein expression was reduced in endometrial compared to prostate 
cancer SPOP mutants, consistent with the BET protein level changes and the transcriptome 
analysis (Fig. 5c). Importantly, in human tumor tissues FOSL1 mRNA and protein 
expression was also decreased in SPOP-mutant endometrial cancer patients, whereby the 
lowest mRNA levels were observed in patients that harbored SPOP mutants shown to have 
in our study the strongest effects on BET protein levels and JQ1-sensitivity (Fig. 5 d,e and 
Supplementary Fig. 7c)30–33.
Next, we asked whether BET protein level changes in response to SPOP mutants and JQ1 
may decrease FOSL1 transcription. To this end, a triple occupancy of BRD2, BRD3, and 
BRD4 has been reported at the FOSL1 promoter (Supplementary Fig. 10d)24. JQ1 treatment 
reduced FOSL1 expression levels in all conditions, while preserving the differences between 
the different types of SPOP mutants (Fig. 5f). Knockdown of individual BET proteins 
decreased FOSL1 transcription in JQ1-resistant Ishikawa cells over-expressing the prostate 
cancer SPOP-Y87C variant (Fig. 4a and Supplementary Fig. 10e). Moreover, FOSL1 
depletion itself directly lowered JQ1 resistance in this setting, indicating a functional 
involvement of this gene downstream of BET protein changes and SPOP mutants (Fig. 5g). 
Taken together, these results suggest that BET protein level changes in response to SPOP 
mutants alter at least in part JQ1 susceptibility through transcriptional regulation of FOSL1.
JQ1 treatment blocks tumor growth in endometrial SPOP mutant xenografts in vivo
Finally, we investigated whether our results on altered JQ1 sensitivity in response to SPOP 
mutants were validated in an in vivo setting. For this purpose, we focused on endometrial 
cancer-associated SPOP mutants because this setting may identify patients with particular 
beneficial responses to BET inhibitors. Indeed, JQ1 efficiently blocked the growth of 
xenograft tumor models established from SPOP-mutant EN cells by reducing cell 
proliferation and inducing apoptosis, whereas Ishikawa-derived tumors were largely resistant 
to JQ1 treatment (Fig. 6a-c). Consistent with in vitro data, forced expression of SPOP-E50K 
or SPOP-S80R sensitized Ishikawa cells to JQ1 in vivo (Fig. 6d,e).
Discussion
Recurrent missense mutations in SPOP – encoding a substrate receptor of a cullin-RING 
ubiquitin ligase - have emerged in 5-10 % of comprehensive prostate and endometrial cancer 
genome sequencing studies2–6. Surprisingly, the specific genetic alterations show no 
overlap between the tumor types, even though they are confined to the same substrate 
recognition domain. While the prostate cancer-associated mutations have been more recently 
shown to stablize protein substrates relevant to prostate tumorigenesis9–12,34, the 
therapeutic implication of both mutation types remain largely elusive.
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Our study identifies the BET proteins (BRD2, BRD3, and BRD4) as bona fide SPOP 
substrates. Small-molecule inhibitors against this group of proteins are under clinical 
investigation in hematological and solid tumors because of their critical importance in 
driving lineage-specific oncogenic transcriptional programs18,21,23,24. We found that 
prostate cancer-associated SPOP mutations impair degradation of BET proteins in line with 
their loss-of-function properties reported previously8,9, while endometrial cancer-associated 
SPOP mutations enhance BET proteins degradation through a gain-of-function mechanism 
(Fig. 6f). The precise structural basis on how endometrial SPOP mutants enhance binding 
and ubiquitylation of BET proteins and other substrates (e.g. DEK) remains to be further 
elucidated. The altered BET protein levels in the SPOP mutant setting influence the 
transcription of established target genes such as FOSL129 and thereby alter the 
susceptibility of cancer cells to BET inhibitors. Of note in this regard, a recent report implies 
enhanced FOSL1 activity as a mechanism of acquired resistance in ovarian cancer cells as 
well35. Overall, our established model extends the list of previously reported mechanisms 
that influence BET inhibitor sensitivity27,36,37 .
BET inhibitors are currently under clinical development and there is a critical need to 
identify patients that may respond to the treatment. Our preclinical study identifies SPOP 
mutations as a clinically detectable biomarker of BET inhibitor response. Thus, the detection 
of specific SPOP mutations may be used to select patients that may (endometrial cancer-
associated SPOP mutations) or may not (prostate cancer-associated SPOP mutations) benefit 
from the BET inhibitors treatment.
More generally, our results suggest a paradigm whereby mutations within the same domain 
of a particular protein evoke opposing drug susceptibilities. Given the increasing use of 
cancer genome information in a clinical setting, caution may be applied to extrapolate 
therapeutic responses based on similar mutations.
Methods
SILAC-labeling and Cell Culture
For SILAC experiments, human endometrial cancer cells Ishikawa were cultured in 
DMEM/F12 media deficient in L-arginine and L-lysine and supplemented with 10% 
dialyzed fetal bovine serum (FBS) (Sigma-Aldrich), penicillin, streptomycin, and L-
glutamine (Invitrogen) and either L-arginine (Arg-0) and L-lysine (Lys-0), L-arginine 
[13C6]HCl (Arg-6) and L-lysine-4,4,5,5-d4 (Lys-4), or [13C6, 15N4]HCl (Arg-10) and L-
lysine [13C6,15N2]HCl (Lys-8) (Sigma-Aldrich) for 14 days (10 doublings). All media were 
supplemented with L-proline to prevent the conversion of arginine to proline38. Specifically, 
isogenic cell lines expressing either vector control (C), wild type SPOP (SPOP-WT) or 
mutants (MTs) were isotopically labeled with SILAC media and grouped into four 
experiments (Supplementary Fig. 1d). Each experiment included a cell line with over-
expression of SPOP-WT for cell line comparison within and across experiments. The 
labeling for this cell line was switched to rule out labeling artifacts in the first three 
experiments. Approximately 100 million cells per condition were washed twice with PBS, 
harvested, and snap frozen.
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K-ɛ-GG profiling and proteome analysis by liquid chromatography mass-spectrometry
Preparation of proteins for mass spectrometry analysis was completed as previously 
described14. Briefly, cell pellets were lysed in an ice cold urea lysis buffer containing, 8 M 
urea, 50 mM Tris HCl, pH 8, 150 mM NaCl, 1 mM EDTA, 2 ug/ml aprotinin (Sigma-
Aldrich), 10 mg/ml leupeptin (Roche Applied Science), 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 50 uM PR-619, and 1 mM chloroacetamide. The lysate was cleared by 
centrifugation at 20,000g for 10min. A bicinchoninic acid (BCA) protein assay (Thermo 
Fisher Scientific) was used to determine the protein concentration of each sample. 
Respective SILAC mixes were created by combining equal amount of protein per SILAC 
state. Proteins were reduced with 5 mM DTT at RT and subsequently alkylated with 10 mM 
iodoacetamide at RT in the dark. Lysates were diluted 1:4 with 50 mM Tris HCl, pH 8 and 
proteins were digested with sequencing grade trypsin using an enzyme to substrate ratio of 
1:50, O/N at 25 C. Digests were quenched with TFA and the peptide solutions were cleared 
by centrifugation prior to desalting. Peptides were desalted using tC18 SepPak SPE 
cartridges (Waters) exactly as previously described14.
Peptides were fractionated offline by basic pH reversed-phase (bRP) chromatography as 
previously described14,39. Input for each bRP separation was equivalent to 30 mg of 
starting protein material (10 mg protein per SILAC state) for replicate. Briefly, dried 
peptides were reconstituted in bRP buffer A (5 mM ammonium formate (pH 10.0)/2% 
acetonitrile). A Zorbax 300 Extend-C18 column (9.4 × 250 mm, 300 Å, 5 µm; Agilent) was 
used for the separation. Using the gradient and flow rate settings previously described14 a 
total of 96 2 ml fractions were collected across the entirety of the bRP separation. For 
proteome analysis, 5% of each fraction was taken and combined in a non-contiguous manner 
such that every 24th fraction was combined to create 24 final fractions. For K-ε-GG analysis, 
the remainder of each fraction was combined in a non-contiguous manner such that every 
eighth fraction was combined to create 8 final fractions. Pooled fractions were dried 
completely using vacuum centrifugation.
For enrichment of K-ε-GG peptides, anti-K-ε-GG antibody from the PTMScan ubiquitin 
remnant motif (K-ε-GG) kit was utilized (Cell Signaling Technology, cat. no. 5562). Prior to 
enrichment, the antibody was cross-linked to protein A beads using dimethyl pimelimidate 
(DMP)14. Peptides were reconstituted in immunoaffinity purification (IAP) buffer and the 
enrichment was completed exactly as previously described14. Briefly, peptides were 
incubated with approximately 31 ug of anti-K-ε-GG antibody beads and incubated for 1 h at 
4 °C with rotation. Beads were washed twice with 1.5 ml of ice-cold IAP buffer followed by 
three washes with ice-cold PBS. K-ε-GG peptides were eluted from the antibody with 2 x 50 
ul of 0.15% TFA. Peptides were desalted using StageTips. StageTips were conditioned by 
washing with 50 ul of 50 % MeCN/0.1% formic acid (FA) followed by 2 x 50 ul of 0.1% 
FA. Peptides were then loaded on StageTips, washed 2 x with 50 ul of 0.1% FA and eluted 
with 50 ul of 50 % MeCN/0.1% formic acid (FA). Eluted peptides were dried completely 
using vacuum centrifugation.
Samples were reconstituted in 3% MeCN/0.1% FA. All samples were analyzed by 
nanoflow-UPLC-HCD-MS/MS using a Q Exactive mass spectrometer (Thermo Fisher 
Scientific) coupled online to an Easy-nLC 1000 system (Proxeon). For K-ε-GG and 
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proteome samples, 4/8 ul and 1/20 ul were injected into the mass spectrometer, respectively. 
Samples were injected at a flow rate of 500 nl/min onto a PicoFrit column (360 µm (OD) × 
75 µm (ID), 10 µm ID tip, 50 cm length (New Objective) self-packed with 24 cm of 
ReproSil-Pur 120 Å, 1.9 µm C18-AQ beads. The nanoflow column was heated to 50 °C 
using a column heater (Pheonix S&T). For LC-MS/MS analyses, the gradient and flow rate 
settings were used as previously described14 and the MS acquisition time used for each K-ε-
GG and proteome sample was 120 min. The Q Exactive was operated by acquiring an MS1 
scan (R=70,000) followed by MS/MS scans (R=17,500) on the 12 most abundant ions. An 
MS1 and MS2 ion target of 3 x 10^6 and 5 x 10^4 ions, respectively was used for 
acquisition. A maximum ion time of 10 ms and 120 ms was used for MS1 and MS2 scans, 
respectively. The isolation width was set to 2.5 m/z, the HCD collision energy was set to 25, 
the dynamic exclusion time was set to 20 s,and the peptide match and isotope exclusion 
functions were enabled. A second round of bRP fractionation, K-ε-GG, and MS analysis 
was completed for experiment 3 and 4 (6 mg per SILAC state for experiment 3 and 10 mg 
per SILAC state replicate 4).
MS Data Analysis
Data were processed using the MaxQuant (version 1.2.2.5) software package. The human 
Uniprot database including 248 common laboratory contaminants was used for searching. 
The enzyme specificity was set to trypsin, the maximum number of missed cleavages was 
set to 2 for proteome data and 4 for K-ε-GG data , the precursor mass tolerance was set to 
20 ppm for the first search, and the tolerance was set to 6 ppm for the main search. 
Carbamidomethylation of cysteines was searched as a fixed modification and oxidation of 
methionines and N terminal acetylation of proteins was searched as variable modifications.
For K-ɛ-GG data, addition of glycine-glycine to lysine was also searched as a variable 
modification. For identification, the minimum peptide length was set to 7, and the false 
discovery rate for peptide, protein, and side identification was set to 1 %. The filter labeled 
amino acids and peptide quantification functions were enabled. For proteome data, 
normalized ratios were obtained from the ”proteinGroups” table. For K-ε-GG data, 
normalized SILAC ratios were obtained from the ”GlyGly(K)Sites” table.
For K-ɛ-GG and proteome datasets, reverse and contaminant hits were removed from the 
analysis. Proteins were considered in the dataset if they were identified and quantified by 2 
or more razor/unique peptides in each SILAC triple-labeled experiment. K-ε-GG peptides 
were considered for the final dataset if the corresponding protein was quantified in the 
proteome data.
To capture ubiquitylation changes associated with protein degradation, we normalized the K-
ɛ-GG changes to their measured protein levels. The leading accesion number was used to 
match the protein and K-ɛ-GG data. Quantitative, protein-normalized measurements were 
available for 17,239 K-ɛ-GG peptides. To assess and highlight which of the significantly 
deregulated K-ɛ-GG peptides were paralleled with opposing effects on total protein 
expression in the MT/WT case, protein normalized K-ɛ-GG MT/WT SILAC ratios were 
multiplied by their corresponding protein level ratio and also by -1 (Supplementary Fig. 2 
and Supplmentary Table 1).
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The original mass spectra have been deposited in the public proteomics repository MassIVE 
and are accessible at ftp://MSV000080401@massive.ucsd.edu when providing the dataset 
password: ubiquitin. If requested, also provide the username: MSV000080401. This data 
will be made public upon acceptance of the manuscript.
Cell culture, Transfection and Infection
Ishikawa cells were purchased from Sigma, RL-952, 22Rv1, MEF-962, VM-CUB1, NCI-
H508 from ATCC, EN from DSMZ, HEC-151 from JCRB. AN3CA, HEC1A, HEC 1B, 
HEC116, SNG-II, EFE184, KLE were kindly provided by Dr. med. Eleftherios Samartzis 
and Dr. med. Konstantin Dedes (University Hospital Zurich). Ishikawa, RL-952 and KLE 
cells were grown in F12/DMEM (Gibco); MEF-962, HEC-151, EN, HEC1A, HEC1B, 
AN3CA, HEC116 and SNG-II in DMEM (Gibco); 22Rv1 and EFE184 in RPMI medium 
(Gibco); all were supplemented with 10% FBS (Gibco), 1% Penicilin/Streptomycin/ L-
Glutamate. All cells were incubated at 37°C and 5% CO2. Cells were routinely tested for 
mycoplasma contamination.
For transient transfection, cells were transfected with either 50 nM siSPOP (Hs_SPOP_7, 
Qiagen), 50 nM siFOSL1 (Hs_FOSL1_1, Hs_FOSL1_2 and Hs_FOSL1_3, Qiagen) or 
siControl (Qiagen) using Fugene (Promega). For stable knockdown experiments, cells were 
infected with pLKO-1 vectors (Sigma) and the following clones were used: SPOP: 
TRCN0000140431 (shSPOP); BRD2: TRCN00000315433 (shBRD2_#1), 
TRCN0000350530 (shBRD2_#2) ; BRD3: TRCN0000021376 (shBRD3_#1), 
TRCN0000021377 (shBRD3_#2); BRD4: TRCN0000021426 (shBRD4_#1) 
TRCN0000021427 (shBRD4_#2), and shBET (5`-TCCAACTGCTATAAGTACAAT-3`); 
CUL-3: TRCN0000073343 (shCUL-3_#1) and TRCN0000073344 (shCUL-3_#2); DEK: 
TRCN0000013104 (shDEK_#1) and TRCN0000013105 (shDEK_#2), TRIM24: 
TRCN0000021259 (shTRIM24_#1) and TRCN0000194983 (shTRIM24_#2), NCOA3: 
TRCN0000370320 (shNCOA3_#1) and TRCN0000365253 (shNCOA3_#2). After infection, 
cells were selected in the presence of puromycin (2 μg/ml). For over-expression a derivate of 
the pLX304 vector was used throughout in which the CMV promoter has been exchanged to 
a PGK promoter and the blastocidin cassette exchanged by mOrange or a puromycin 
resistance cassette (pLX_TRC_307, available at Addgene as Plasmid 41392, pCW107). All 
ORFs were cloned into pLX_TRC_307-mOrange using Nhe1 and Mlu1.
Dose response curves and cell growth assay
Cells were seeded (between 1x103and 1x104) in 96-well plate. Cells were consequently 
treated with serial dilutions of JQ1 or OTX-015 in media for dose response curves or left 
untreated for cell growth assays. After 96h of treatment in the case of dose response and 6 
days for cell growth assays, respectively, cells were washed with PBS and stained with 
0.5 % crystal violet solution in 25% methanol. Crystal violet was then solubilized with 10 % 
Acetic acid and absorbance (OD, 590 nm) was measured in a microplate reader.
Clonogenic assay in methylcellulose
Cells were seeded (between 5x103and 1x104) in methylcellulose (Methocult H4100, 
StemCell Technologies) in duplicate and treated with vehicle (0.1% DMSO) or drug (JQ1). 
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Cells were incubated at 37°C and 5% CO2 for 7-14 days and colonies were stained with 
MTT solution at 37°C overnight and absorbance (OD, 590 nm) was measured in a 
microplate reader.
Xenograft Model
All animal experiments were carried out in female athymic nude mice (Balb/c nu/nu, 4–6 
weeks old) accordingly to protocol approved by the Swiss Veterinary Authority (No. 
TI-14-2014). 2x106 Ishikawa and EN cells were resuspended in 200 μl of PBS and 
subcutaneously injected into the dorsal flank on both sides of nude mice. Once tumors 
reached approximately 100 mm3, mice were randomized and intraperitoneally administrated 
either with vehicle or with JQ1 at 50 mg/kg (twice per day) for indicated time. Tumor 
growth was recorded using digital caliper and tumor volumes were calculated using the 
formula (L x W2) / 2, where L=length and W=width of tumor. At the end of the experiment, 
mice were sacrified, tumors extracted, weighed and histologically analyzed by a board-
certified pathologist (J.P.T.) by H&E staining and immunohistochemistry for anti-cleaved 
Caspase-3 (Cell Signaling protocol).
Antibodies, Immunoblotting, and Immunoprecipiation
Antibodies used in immunoblotting and immunoprecipitation assays were: anti-BRD2 
(A302-583A, Bethyl Labs), anti-BRD3 (Sc-81202, Santa Cruz), anti-BRD4 (Sc-48772, 
Santa Cruz), anti-SPOP (ab81163, Abcam), anti-TRIM24 (Sc-271266, Santa Cruz), anti-
NCOA3 (2126, Cell Signaling), anti-DEK (610948, BDBioscience), anti-ERG (Sc-271048, 
Santa Cruz), anti-FOSL1 (5281, Cell Signaling), anti-VCL (4650, Cell Signaling), anti-ß-
actin (4967, Cell Signaling), anti-HA (9658, Sigma), anti-Cleaved Caspase-3 (Asp175) 
(9661, Cell Signaling). All antibodies were employed at dilutions suggested by the 
manufacturers.
For immunoblotting, cells were washed with PBS and subsequently lysed in RIPA buffer 
(Sigma) and sonicated. Protein concentration was determined using the BCA reagent 
(ThermoFisher), same amounts of protein were separated by SDS-PAGE (Biorad) and 
transfered onto PVDF membrane (ThermoScientific). The membrane was incubated for one 
hour in 5% nonfat dry milk/TBS-T blocking buffer followed by incubation with the primary 
antibody overnight at 4°C. The membrane was washed with TBS-T followed by incubation 
with horseradish peroxidase-conjugated secondary antibody (Promega).
To detect interactions of SPOP and HA-BRD3, cells were lysed in 1 % NP40 buffer (50mM 
Tris-HCl pH 7.4, 150 mM NaCl, 1 % NP40) with 2x protease inhibitor cocktail (Complete, 
Roche), sonicated, and 3 mg of lysate were incubated overnight with 2 μg of anti-HA-tag or 
control mouse IgG antibody (sc-2025, Santa Cruz Biotechnology) at 4 °C. Subsequently, 
antibodies were collected by 25 µl protein A/G magnetic beads (88803, Fisher Scientific) for 
2h, followed by 2 washing steps with 1 % NP40 buffer. Proteins were eluted by addition of 
1x SDS-sample buffer under reducing conditions at 95 °C for 5 min. Quantitative analysis of 
the Western blots for proteins was normalized to VCL/ACTB expression.
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MG-132 and Cycloheximide (CHX) were purchased from Sigma and used at 10 μM and 100 
μg/ml in all experiments, respectively. (+) - JQ1 and OTX-015 were purchased from 
Selleckchem and used at the indicated concentrations.
In Vivo Ubiquitylation Assay
293T cells were transiently transfected with indicated plasmids: pCW107-BRD3-WT or 
BRD3-Degron-MT (2 μg), pCW107-SPOP-WT or SPOP-MT (2 μg), CMV-8x Ubi-His (2 
μg). 42 hours later, cells were treated with MG-132 or DMSO for additional 3 hours. Cells 
were then washed with PBS and collected by centrifugation. Small amount of cells was 
lysed in RIPA buffer and the rest in Buffer C (6M guanidine –HCL, 0.1 M Na2HPO4/
NaH2PO4, 10mM Imidazole, pH=8). The whole cells extract was sonicated and incubated 
with 60 μl of Ni-NTA agarose (Sigma) overnight at 4°C. Next, Ni-NTA beads were washed 
once with Buffer C, twice with Buffer D (1 volume of Buffer C: 3 volumes of Buffer E) and 
once with Buffer E (25 mMTris-HCL, 20 mM Imidazole, pH=6.8). Elution of bound 
proteins was processed by boiling in 1x SDS loading buffer containing 300 mM Imidazole. 
Samples were loaded, separated by SDS-PAGE, and detected by immunoblotting.
In Vitro Ubiquitylation and Binding assays
Wild-type and SPOP-binding mutant (Degron-MT) constructs of HA-tagged human BRD3 
were purified from transiently transfected HEK-293T cells. Wild-type and mutant human 
SPOP species were cloned, expressed and purified as described previously, using a GST- 
instead of a MBP-affinity tag7., KLHL9, KLHL13, KLHL21, and Cdc34b were cloned, 
expressed and purified from E. coli as described previously40. CUL3 and RBX1 were 
purified in a pre-assembled complex from insect cells, and neddylated in vitro using purified 
components as described previously41. In vitro ubiquitylation reactions with a total volume 
of 15 μl were assembled as follows: 107 HA-BRD3-expressing HEK-293T cells were 
harvested and lysed by sonication in IP buffer (20 mM Tris-Cl pH 7.4, 150 mM NaCl, 5% 
glycerol, 1 mM TCEP, 1x Roche protease inhibitor cocktail). Immunoprecipitates were 
prepared with 10 μL of anti-HA affinity gel (Sigma) and washed with IP buffer. For 
respective samples 2 μl HA-BRD3 IP resin were used and supplemented with 0.3 μM SPOP, 
KLHL9, KLHL13, or KLHL21, 0.2 μM CUL3-Nedd8/RBX1, 0.7 μM Cdc34, 0.2 μM UbE1 
(Boston Biochem) and, 25 μM ubiquitin (BostonBiochem) in ubiquitylation buffer (3 mM 
ATP, 10 mM MgCl2, 50 mM Tris-Cl pH 7.6, and 0.5 mM DTT). Reactions were incubated at 
37°C for 45 minutes and stopped by addition of SDS sample buffer. Samples were separated 
by SDS-PAGE and visualized through chemiluminescence using using anti-HA (Sigma; 
A2095), HRP-coupled goat anti-mouse IgG (Biorad; 170-6516), Clarity™ Western ECL 
Blotting Substrate (Biorad; 1705061) and Fusion FX imaging platform (Vilber Lourmat).
For co-immunoprecipitation experiments in vitro, 1 μM recombinant SPOP-WT or mutants 
and 1 μl of HA-BRD3-WT IP resin were incubated in 200 μl IP buffer (20 mM Tris-Cl pH 
7.4, 150 mM NaCl, 5% glycerol) for 1h at 4°C. Thereafter, resin was washed twice in the 
same buffer and samples were separated by SDS-PAGE and visualized through 
chemiluminescence using using anti-HA and anti-SPOP (see above).
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RNA was extracted using the Rnasy kit (Qiagen) and processed by Kapa SybrFAST one-
Step qRT-PCR kit according to manufacturer`s instructions. q-PCR was undertaken on an 
Applied Biosystems StepOnePlus System. The target mRNA expression was quantified 
using ∆∆Ct method and normalized to Cyclophilin expression. The following primers were 
used: BRD2, forward 5`-CTACGTAAGAAACCCCGGAAG-3’, reverse 5`-
GCTTTTTCTCCAAAGCCAGTT-3’; BRD3, forward 5`-CCTCAGGGAGATGCTATC-
CA-3’, reverse 5`-ATGTCGTGGTAGTCGTGCAG-3’; BRD4, forward 5`-CTCCTC-
CTAAAAAGACGAAGA-3’, reverse 5`-GCCCCTTCTCTTTTTGACTTCGGA-3’; 
TRIM24, forward 5`-CAGCCACAAATGCCTAAGCAG-3’, reverse 5`-
GTGTTGGGAACTTGGATAACTGG-3’; SPOP, forward 5`-
GAAATGGTGTTTGCGAGTAAACC-3’, reverse 5`-GCCCGAA-
CTTCACTCTTTGGA-3’; FOSL1, forward 5’-CTGCAGGCGGAGACTGACAA-3’ , 
reverse 5’-TCCGGGATTTTGCAGATGGG-3’; Cyclophilin, forward 5’-
CAGGTCCTGGCATCTTGTCC -3’, reverse 5’-TTGCTGGTCTTGCCATTCCT-3’.
DNA and RNA sequencing of endometrial cell lines
Whole exome sequencing was performed for all endometrial cancer cells line profiled in the 
Cancer Cell Line Encyclopedia (CCLE)42. This data set was used to determine mutation 
status for SPOP cell lines included in this study. In addition, RNA sequencing was 
performed at the Broad Institute using the Illumina TruSeq protocol for 17 CCLE cell lines. 
Reads were aligned to the human reference genome build hg19 using TopHat version 1.4, 
and mRNA experssion levels were determined using RNA-SeQC. RPKM values for each 
cell line were correlated with the median RPKM values of endometrial cancer tissues with 
recurrent SPOP point mutations identified in the TCGA portal6. A threshold of 10 RPKM 
was used to determine the overlay of robustly expressed genes in the cell lines with the 
genes expressed in human tumor tissues.
For the analysis of transcriptional output changes in response to SPOP mutants, isogenic 
Ishikawa cells stably overexpressing either SPOP-WT or SPOP mutants (endometrial-E50K, 
E47K and prostate-Y87C, W131G) were generated. RNA-sequencing was performed on 
cells either untreated or treated with JQ1 (500 μM or 2 μM) for 4 hours (Supplementary 
Table 2). Total RNA was extracted using the Rnasy kit (Qiagen) and sample quality was 
assessed using Agilent Bioanalyzer. Library preparation (Illumina unstranded True Seq 
Library incl poly(A)enrichment) and RNA sequencing (Illumina NextSeq high output, 
v2,1x75bp) was performed by Microsynth. Quality of the sequencing was analysed 
according to Phred score of Illumina and FastQC (add version). Mapping to Hg38 was 
pursed by STAR 2.52b. Not expressed genes with counts per million (cpm) <0.5 mapped 
reads have been filtered. Subsequently, counts were normalized based on the number of 
reads acquired per sample, transformed in log2 and subjected to voom function of limma 
package. Signatures were derived comparing samples in Supplmentary Table 2 and the 
following filters were used to define differentially expressed genes: cpm>45 in at least 2 
samples, adjusted p-value<0.05 (according Benjamini-Hochberg test), IIogFCI>0.9.
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We used a previously characterized cohort of primary prostate tumors with annotated SPOP 
mutations by high resolution melt analysis assay followed Sanger sequencing of exon 6 and 
73. Due to tissue loss (a common problem encountered with tissue microarrays) only a 
subset were histologically analyzable. These tumors represent are part of tissue microarrays 
composed of paraffin-embedded prostate tissue cores from two different institutes of 
pathology. As previously published, specimens were collected between 1993 and 2007 from 
the Institute of Surgical Pathology, University of Zurich, Switzerland, and the Institute of 
Pathology, University of Regensburg, Germany43. The local scientific ethics committees 
approved both cohorts (approval no.: StV-Nr. 25/2007). Primary endometrial cancer tissues 
were retrieved from different sources. Tissue sections of 19 tumors culled from the literature 
with annotated, recurrent SPOP mutations were collected as follows: TCGA-D1-A0ZO, 
TCGA-D1-A167, TCGA-D1-A168, and TCGA-D1-A17D from the Mayo clinic6, TCGA-
B5-A0JY, TCGA-B5-A0K0, TCGA-NA-A5I1 from the Duke Cancer Center6, TCGA-BS-
A0UT from the University of Hawaii Cancer Center6, TCGA-FI-A2EW from the 
Washington University6, TCGA-N9-A4Q8, TCGA-DI-A1NN from the MD Anderson 
Cancer Center6, 2001-02-G049T, 2005-08-G674T, MAD04-00646T, 1090095AT, 
1090076AT from the Cooperative Human Tissue Network (CHTN)4, 119, 127, 136 from the 
Oregon Health & Science University (OHSU)5.
We characterized additional 84 primary endometrial cancer tissues samples by targeted DNA 
sequencing (36 endometrioid carcinomas, 26 serous carcinomas, 11 clear cell carcinomas, 
and 11 carcinosarcomas) from two different cohorts from Basel and Zurich44,45,46. 
Therefore, two 0.6-mm diameter tumor tissue cylinders were punched out of paraffin-
embedded tissue blocks and DNA isolated using the Maxwell® 16 FFPE Tissue LEV DNA 
Purification Kit (Promega) according to the manufacturer’s instructions. DNA was 
quantified using dsDNA HS Assay Kit with Qubit 2.0 (Thermo Fisher Scientific/Life 
Technologies) and 20 ng were used to prepare libraries using Ion AmpliSeq™ Library Kit 
2.0 according to the manufacturer’s instructions. A custom panel was applied for PCR-based 
amplification of SPOP gene. Libraries were labeled with the Ion Xpress™ Barcode Adapters 
1-96 Kit (Thermo Fisher Scientific/Life Technologies) and quantified by qPCR with the Ion 
Library Quantitation Kit (Thermo Fisher Scientific/Life Technologies). Twenty to twenty-six 
libraries were multiplexed for template preparation and enrichment using Ion PI™ Hi-Q™ 
OT2 200 Kit (Thermo Fisher Scientific/Life Technologies). Enriched samples were then 
loaded on an Ion PI™ Chip v3 (Thermo Fisher Scientific/Life Technologies) and sequenced 
on the Ion Proton™ System using Ion PI™ Hi-Q™ Sequencing 200 Kit (Thermo Fisher 
Scientific/Life Technologies). Sequencing run quality metrics were taken from the Torrent 
Suite™ Software (Thermo Fisher Scientific/Life Technologies) for each run. Sequencing 
data was then analyzed with Ion Reporter™ Software (Thermo Fisher Scientific/Life 
Technologies). We identified another SPOP-D140Y mutated serous cancer, while the 
remaining cases did not harbor any additional recurrent mutations nor any other type of 
mutation in SPOP at an allelic fraction higher than 0.2. The study was approved by the 
scientific ethics committee (approval no.: KEK-ZH-NR: 2010-0358).
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For the detection of BET and FOSL1 proteins, slides were first dehydrated. For antigen 
retrieval, slides were incubated in a waterbath at 98 °C for 20 min using a citrate bufffer at 
ph 6 (BETs) or ph 9 (FOSL1) (Diapath T0050). For prostate cancer tissue-microarrays, the 
antigen retrieval for BRD2 and FOSL1 was extended to 40 min in total. Subsequently, slides 
were cooled to room temperature for 20 min and endogenous peroxidays blocked for 
additional 10 min with 3 % H2O2 (VWR 23615.248). After washing, slides were incubated 
for 10 min with a protein block solution (Dako X0909). Then, slides were incubated with the 
primary antibodies at following concentrations: BRD2 (Abcam ab13960; 1:500), BRD3 
(Bethyl A302-368A; 1:50), BRD4 (Abcam ab128874; 1:400), and FOSL1 (Sigma Aldrich 
AV31377; 1:2000) for 1 h in antibody diluent reagent solution (Life Technologies 003118). 
For prostate cancer tissue-microarrays, the BRD2 antibody was used at a dilution of 1:200. 
Thereafter, slides were washed and incubated with biotinylated anti-rabbit IgG (Vector 
BA-1000) in PBS for 30 minuts at room temperature and subsequently washed and 
incubated another 30 min with Vectastin ABC kit at a dilution of 1:150 in PBS. Detections 
were performed using the ImmPACT DAB system (Vector SK-4105) for 4 minutes at room 
temperature followed by nucelar statining with Mayer Hematoxilin (Diapath C0303). 
Immunohistochemical staining was evaluated as follows for BET proteins: No detectable 
staining in more than 70% of tumor cell nuclei was referred as negative, 30% or more tumor 
cell nuclei weakly stained (discernable nucleoli) as weak and more than 30% of nuclei 
strongly stained (invisible nucleoli) as strong.
Statistical analysis
GraphPad Prism version 7.00 (GraphPad Software) was used for analysis. Data are depicted 
as means ± SEM unless otherwise specified. An unpaired, two-tailed independent Student's t 
test with unequal variance assumption was performed to analyze cell culture experiments. 
Two-way ANOVA (Dunnett’s post test) was used for multiple comparisons. Extra-sum of 
squares F-test was used to determine statistical significance of dose response curves. The 
Spearman correlation coefficient was used to compare RNAseq expression data from SPOP-
mutant human tumors, and BET protein levels with endometrial cell line data. Kendall’s tau-
b was used to test correlation of immunohistochemical staining with SPOP mutation status.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Endometrial and prostate cancer SPOP mutants induce opposing effects on BET 
protein levels.
(a) Outer surface of the SPOP substrate recognition domain with recurrently mutated amino 
acid residues highlighted in blue for prostate cancer and red for endometrial cancer, 
respectively7. Substrate in green in the substrate binding cleft. (b) Scatter plot of protein 
expression changes of SPOP mutants (MTs) vs. SPOP wild type (WT) in Ishikawa 
endometrial cancer cells, dotted red line = 2 s.d. (c) Representative Western blot (WB) 
validation for indicated proteins in Ishikawa cells stably expressing vector control, SPOP-
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WT, or endometrial cancer SPOP-MTs (n=5). (d) Representative WB for indicated proteins 
in Ishikawa endometrial cancer cells expressing prostate cancer SPOP-MTs (n=3). (e) 
Representative WB for indicated proteins in 22Rv1 prostate cancer cells stably expressing 
prostate cancer SPOP-MTs (n=3). (f) Representative images of primary human endometrial 
cancer tissues stained for BRD2, BRD3 and BRD4 with corresponding expression analysis 
on primary tumors stratified accordingly SPOP mutation status. Scale bars, 20µm. (g) 
BRD2, BRD3 and BRD4 expression analysis of primary human prostate cancer tissues 
stratified accordingly SPOP mutation status (R correlation coefficient and p values are 
derived from Kendall’s tau-b). N indicates the number of independent experiments 
performed.
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Figure 2. BET proteins are bona fide substrates of wild type SPOP.
(a) Schema of BET proteins with bromodomain 1 and 2 (BD1 and BD2), extraterminal (ET) 
domain, and C-terminal domain (CTD), ubiquitylated lysines (K-ɛ-GG) detected by mass-
spectrometry, and SPOP degron motif. (b) Effect of transient SPOP-WT overexpression on 
protein levels of HA-BRD3-WT and HA-BRD3-Degron-MT assessed by WB in Ishikawa 
cells (n=3). (c) Interaction between SPOP-WT and BRD3-WT or HA-BRD3-Degron-MT. 
HA-immunoprecipitation (IP) and whole cell extract (WCE) of transiently transfected 293T 
cells (n=3). (d) In vivo ubiquitylation of HA-BRD3-WT and HA-BRD3-Degron-MT by 
SPOP-WT. 293T cells transfected with 8xHis-Ubiquitin (Ub) and indicated constructs 
followed by MG132 treatment. 8xHis-Ub pull down using nickel beads on lysed cells (n=3). 
(e) HA-BRD3 protein level by WB in Ishikawa cells transiently expressing SPOP-WT and 
HA-BRD3 with or without MG132 treatment (n=3). (f) Representative WB for indicated 
proteins upon knockdown of SPOP with shRNA (left) or siRNA (right) in Ishikawa cells 
(n=3). Representative WBs are shown. N indicates the number of independent experiments 
performed.
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Figure 3. BET proteins are differentially ubiquitylated and degraded by endometrial and 
prostate SPOP mutants.
(a) Representative WB (n=4) of BET proteins and SPOP in Ishikawa and EN human 
endometrial cell lines. Statistical significance was determined by unpaired, two-tailed 
Student’s t-test (n.s., non-signicant). (b) Representative WB of indicated proteins in 
Ishikawa and EN cells with or without MG132 treatment (n=3). (c) Representative WB of 
indicated proteins after cycloheximide (CHX) treatment in Ishikawa and EN cells (n=3). (d) 
Interaction between HA-BRD3 and SPOP-WT, endometrial cancer mutants (SPOP-E50K, -
R121Q), and one prostate cancer mutant (SPOP-W131G). HA-IP and WCE of transiently 
transfected 293T cells overexpressing HA-BRD3 and indicated SPOP constructs (n=3). (e) 
Effects of SPOP-WT and SPOP mutants on in vivo ubiquitylation of HA-BRD3 (n=3). (f) In 
vivo ubiquitylation of HA-BRD3-WT or HA-BRD3-Degron-MT by SPOP-E50K (n=3). 
Representative WBs are shown. N indicates the number of independent experiments 
performed.
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Figure 4. Cancer-type specific SPOP-mutants alter BET inhibitor sensitivity in an opposing 
manner.
(a) Response to JQ1 in Ishikawa cells stably over-expressing endometrial (E47K, E50K, 
E78K, S80R, M117V, R121Q, D140N) and prostate cancer (Y87C, F102C, W131G, F133L) 
SPOP mutants in 3D semi-solid cell culture condition (n=3). P values are indicated above 
the compared bars (two-way ANOVA with Dunnett’s post test, DF= 112 (degrees of 
freedom)). (b) Correlation of IC50 (JQ1) shown in Supplementary Fig. 7c with BET protein 
levels quantified by mass-spectrometry in Ishikawa cells stably expressing recurrent 
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endometrial SPOP-MTs (r- and p value Spearman rank correlation). (c) Response to JQ1 
(250nM) of Ishikawa cells stably overexpressing SPOP-E50K and different BET protein 
degron mutant constructs (Degron MT) (n=3). (d) Effect of single shRNA-mediated 
depletion of BRD2, BRD3 and BRD4 on JQ1 (200nM) sensitivity in Ishikawa-SPOP-Y87C 
cells (n=3). (e) JQ1 sensitivity of SPOP-WT Ishikawa, SPOP-R121Q-mutant EN human 
endometrial cancer cell lines; SPOP-E47K-mutant NCI-H508 human large intestine cancer 
cell line and SPOP-E50K-mutant VM-CUB1 human urothelial cancer cell line in 3D semi-
solid culture (n=4). P values are indicated above the compared bars (two-way ANOVA with 
Dunnett’s post test, DF= 30). N indicates the number of independent experiments 
performed. All error bars, mean ± SEM. Statistical significance was determined by unpaired, 
two-tailed Student’s t-test unless otherwise specified (*P < 0.05, **P < 0.01, ***P < 0.001).
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Figure 5. Downregulation of FOSL1 sensitizes to JQ1 treatment.
(a) Venn diagram depicting the overlap of significantly differentially expressed genes in 
Ishikawa cells stably expressing either endometrial (E47K, E50K) or prostate (Y87C, 
W131G) cancer SPOP MTs without or with JQ1. Overlay is significant p value < 0.05 
(Benjamini-Hochberg test). (b) Heat map showing the fold change of the 16 genes included 
in the intersection of panel a. (c) FOSL1 mRNA (normalized to Cyclophilin) and protein 
levels of Ishikawa cells stably expressing SPOP-WT and either endometrial or prostate 
cancer SPOP MTs (n=4). (d) FOSL1 mRNA expression in endometrial30 and prostate31–33 
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cancer patient datasets stratified accordingly to SPOP status. P value was derived from an 
unpaired t-test with Welch’s correction. (e) Representative images of human primary 
endometrial cancer tissues stained for FOSL1 with corresponding expression analysis on 
human primary tumors stratified accordingly to SPOP mutation status (p value Kendall’s 
tau-b). Scale bars, 80µm. (f) FOSL1 mRNA and protein expression levels after JQ1 (500nM) 
treatment in Ishikawa cells stably expressing SPOP-WT and either two endometrial (E47K, 
E50K) or two prostate (Y87C, W131G) cancer SPOP MTs (n=3). (g) Dose-response curves 
to JQ1 of Ishikawa-SPOP-Y87C cells upon FOSL1 knockdown (n=3). P value is indicated 
below the dose-response curves by extra-sum of squares F test. Corresponding WB 
validation of FOSL1 knockdown. N indicates the number of independent experiments 
performed. All error bars, mean ± SEM. Statistical significance was determined by unpaired, 
two-tailed Student’s t-test unless otherwise specified (n.s., non-signicant, *P < 0.05, **P < 
0.01, ***P < 0.001).
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Figure 6. Endometrial SPOP mutants sensitize to JQ1 treatment in vivo.
(a) Tumor growth kinetics and graph showing the individual tumor weight with (n=9) or 
without (n=7) JQ1 in xenografts established from EN. (b) Tumor growth kinetics and graph 
showing the individual tumor weight with (n=7) or without (n=7) JQ1 in xenografts 
established from Ishikawa. (c) Representative histology and quantification of mitotic and 
apoptotic cells in EN and Ishikawa xenografts treated either with vehicle or JQ1. (d) Tumor 
growth kinetics and graph showing the individual tumor weight with (n=7) or without (n=6) 
JQ1 in xenografts established from Ishikawa stably over-expressing SPOP-E50K. (e) Tumor 
Janouskova et al. Page 28













growth kinetics and graph showing the individual tumor weight with (n=6) or without (n=7) 
JQ1 treatment in xenografts established from Ishikawa stably over-expressing SPOP-S80R. 
Representative images of tumors for each xenograft group are shown. Mean tumor volume + 
SEM is shown. Statistical significance was determined by unpaired, two-tailed Student’s t-
test (*P < 0.05, **P < 0.01, ***P < 0.001). (f) Model showing the differential effect of 
cancer-specific SPOP mutations on both BET protein levels and sensitivity to BET 
inhibitors.
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